Vmn2r65 Inhibitors
Vmn2r65 can lead to the functional inhibition of this receptor through various biochemical interactions. Phosphoramidon and Thiorphan are two such inhibitors, both targeting the neutral endopeptidase (NEP), which is responsible for the degradation of peptides that act as ligands for Vmn2r65. Their inhibition can increase the concentration of peptide ligands, which may saturate and desensitize Vmn2r65. Similarly, Captopril, an angiotensin-converting enzyme (ACE) inhibitor, can indirectly elevate peptide ligand levels due to the cross-reactivity of ACE with NEP, possibly resulting in the desensitization of Vmn2r65 as well.Dithiothreitol (DTT) disrupts the function of Vmn2r65 by reducing disulfide bonds, critical for maintaining the protein's conformation. This reduction can lead to a loss of proper protein structure and function. Moreover, metal ions such as those introduced by Zinc Sulfate and Copper(II) sulfate can bind to specific sites on Vmn2r65, potentially modifying its conformation and inhibiting its function. Zinc ions might stabilize an inactive conformation of the receptor, while copper ions could alter the receptor's structure or obstruct the ligand-binding site. Methimazole interacts with thiol groups within proteins and could potentially form disulfide bonds with Vmn2r65, leading to inhibition.
Chloroquine disrupts the functional expression of Vmn2r65 on the cell surface by alkalinizing intracellular compartments necessary for receptor trafficking. Bafilomycin A1 and Concanamycin A, both V-ATPase inhibitors, prevent the acidification of intracellular compartments, crucial for the proper processing and maturation of Vmn2r65. E-64, an inhibitor of cysteine proteases, can block the processing enzymes essential for Vmn2r65's functionality. Lastly, GW4869 inhibits neutral sphingomyelinase (nSMase), affecting the production of ceramide within lipid rafts where Vmn2r65 may reside for signaling, potentially leading to the receptor's functional inhibition due to disrupted microdomains.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Phosphoramidon | 119942-99-3 | sc-201283 sc-201283A | 5 mg 25 mg | $199.00 $632.00 | 8 | |
Phosphoramidon is a potent inhibitor of neutral endopeptidase (NEP), which is involved in the degradation of many peptides that can act as ligands for various vomeronasal type 2 receptors (V2Rs), including Vmn2r65. Inhibition of NEP can lead to an increase in the concentration of peptide ligands, which could saturate Vmn2r65, potentially leading to receptor desensitization and functional inhibition. | ||||||
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
Captopril is an angiotensin-converting enzyme (ACE) inhibitor. While ACE primarily targets the renin-angiotensin system, it can have cross-reactivity with NEP. By inhibiting ACE, captopril may indirectly increase peptide ligands that are also substrates for NEP, leading to potential desensitization of Vmn2r65. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc ions can act as allosteric modulators of various receptors. For Vmn2r65, which may have binding sites for zinc ions, the binding of zinc could stabilize a conformation that is inactive, thereby inhibiting its function. | ||||||
Copper(II) sulfate | 7758-98-7 | sc-211133 sc-211133A sc-211133B | 100 g 500 g 1 kg | $46.00 $122.00 $189.00 | 3 | |
Copper ions can bind to certain protein domains and alter their structure and function. If Vmn2r65 is sensitive to copper binding, this could inhibit the receptor's function by altering its conformation or blocking the ligand-binding site. | ||||||
Methimazole | 60-56-0 | sc-205747 sc-205747A | 10 g 25 g | $70.00 $112.00 | 4 | |
Methimazole is known to inhibit the enzyme thyroperoxidase, but it can also interact with thiol groups in proteins. If Vmn2r65 contains crucial thiol groups for its activity, methimazole could form a disulfide bond with these groups, inhibiting the function of the protein. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is known to alkalinize intracellular compartments such as endosomes and lysosomes. If Vmn2r65 undergoes trafficking through these compartments for proper surface expression, chloroquine could disrupt this process, inhibiting the receptor's functional expression on the cell surface. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase). By inhibiting V-ATPase, it can disrupt the acidification of intracellular compartments. This can affect the processing and maturation of Vmn2r65, leading to its functional inhibition. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E-64 is an irreversible inhibitor of cysteine proteases. If Vmn2r65 requires the activity of cysteine proteases for its maturation or function, E-64 could inhibit these enzymes and thus inhibit the function of Vmn2r65. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is another inhibitor of V-ATPase, similar to Bafilomycin A1. By inhibiting the acidification within intracellular compartments necessary for protein processing, Concanamycin A could inhibit the maturation and function of Vmn2r65. | ||||||
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
GW4869 is an inhibitor of neutral sphingomyelinase (nSMase), which is involved in the production of ceramide, a component of lipid rafts. If Vmn2r65 is localized in lipid rafts for proper signaling, inhibition of nSMase by GW4869 could disrupt these microdomains and inhibit Vmn2r65 function. | ||||||